TY - JOUR
T1 - More than just B-cell inhibition
AU - Ruderman, Eric M.
AU - Pope, Richard M.
N1 - Funding Information:
This work was supported in part by National Institutes of Health grant AR055240.
PY - 2011/8/30
Y1 - 2011/8/30
N2 - Despite tremendous advances in the therapy of rheumatoid arthritis (RA), there remains interest in oral agents that may off er benefi ts that are similar to, or better than, those of biologic therapies. In their paper, Chang and colleagues demonstrate the eff ectiveness of a Bruton tyrosine kinase (Btk) inhibitor in two models of RA. Btk inhibition impacts several pathways aff ecting both B-cell and macrophage activation, making it a promising target in RA. However, other kinase inhibitors have failed to transition from animal models to human therapy, so it remains to be seen whether a Btk inhibitor will have a role in the RA treatment armamentarium.
AB - Despite tremendous advances in the therapy of rheumatoid arthritis (RA), there remains interest in oral agents that may off er benefi ts that are similar to, or better than, those of biologic therapies. In their paper, Chang and colleagues demonstrate the eff ectiveness of a Bruton tyrosine kinase (Btk) inhibitor in two models of RA. Btk inhibition impacts several pathways aff ecting both B-cell and macrophage activation, making it a promising target in RA. However, other kinase inhibitors have failed to transition from animal models to human therapy, so it remains to be seen whether a Btk inhibitor will have a role in the RA treatment armamentarium.
UR - http://www.scopus.com/inward/record.url?scp=80052247992&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052247992&partnerID=8YFLogxK
U2 - 10.1186/ar3439
DO - 10.1186/ar3439
M3 - Editorial
C2 - 21878134
AN - SCOPUS:80052247992
VL - 13
JO - Arthritis Research and Therapy
JF - Arthritis Research and Therapy
SN - 1478-6354
IS - 4
M1 - 125
ER -